Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist

Urologia Internationalis

Volumn 64, Issue 1, 2000, Pages 18-23

  Hofer, Christian ^a   Sauerstein, Peter ^a   Wolter, Christian ^b   Scholz, Michael ^a   Hartung, Rudolf ^a   Breul, Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Prostate cancer; Prostate specific antigen, free, total, age specific

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ASSAY; REFERENCE VALUE; STATISTICAL ANALYSIS; TRANSURETHRAL RESECTION; ULTRASOUND;

EID: 0034050970     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030476     Document Type: Article

References (28)

1. Wingo PA, Tong T, Bolden D: Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Bundesminister für Gesundheit (ed): Daten des Gesundheitswesens. Schriftenreihe des Bundesministeriums für Gesundheit. Baden-Baden, Nomos, 1991.
3. Bangma CH, Kranse R, Blijenberg BG, Schröder FH: The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995;46:779-784.
4. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in early detection of prostate cancer: results of multicenter clinical trial of 6630 men. J Urol 1994;151: 1283-1290.
5. Kirkels WJ, Schröder FH, Damhuis RS, Nijs HG, Roobol-Bouts M: A European study for screening of adenocarcinoma of the prostate. Report of a pilot study. J Urol 1993;149(suppl): 289A.
6. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH: The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 1992;147:817-821.
7. Carter H, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, Chan DW, Fozard JL, Walsh PC: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-3328.
8. Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71: 2031-2040.
9. Etzione R, Shen Y, Petteway JC, Brawer MK: Age-specific prostate-specific antigen: A reassessment. Prostate 1996;7(suppl):70-77.
10. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum PSA in community-based population of healthy men. JAMA 1993;270:860-864.
11. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51:222-226.
12. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T: Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 1991;37:1618-1625.
13. Van Iersel MP, Witjes WPJ, Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMJ: Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate 1996;7(suppl): 48-57.
14. Catalona WJ: Clinical utility of measurement of free and total prostate-specific antigen (PSA): A review. Prostate 1996;7(suppl):64-69.
15. Demura T, Shinohara N, Tanaka M, Enami N, Nonomura K, Koyanage T: Ratio of free and total prostate specific antigen: A method of detecting prostate cancer in the cases with PSA levels of 10 ng/ml or lower. J Urol 1996;155: 368.
16. Reissigl A, Klocker H, Pointer J, Ennemoser O, Fink K, Bartsch G: Improvement of prostate cancer (PCA) screening by determination of the ratio free/total (f/t) PSA in addition to PSA levels. A prospective study. J Urol 1996;155: 370.
17. Oesterling JE, Wojno KJ, England B, Vessella RL, Lange PH, Noteboom J, Wright GL, Schellhammer PF, Weigand FA, Olson RM, Dowell DL: A comparison of free to total PSA (F/T) ratio to total PSA for distinguishing benign prostatic hyperplasia (BPH) from prostate cancer (CaP) using the Abbott AxSYM System. J Urol 1996;155:370.
18. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L: Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate 1996; 7(suppl):3-16.
19. Niesel T, Breul J, Löffler E, Leyh H, Hartung R: Die ultraschallgesteuerte transrektale «mapping» Biopsie der Prostata - Korrelation zum Operationspräparat und Verträglichkeit beim Patienten. Akt Urol 1995;26:244-248.
20. Weining C, Semjonow A, Hertle L: Nutzen verschiedener Verfahren zur Verbesserung der Spezifität von PSA in the Prostatakarzinomdiagnostik. Urologe B 1997;37:216-220.
21. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997;157:2191-2198.
22. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996; 48(suppl):55-61.
23. Higashihara E, Nutahara K, Kojima M, Okegawa T, Miura I, Miyata A, Kato M, Sugisaki H, Tomaru T: Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol 1996;156:1964-1968.
24. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277: 1452-1455.
25. Abrahamsson PA, Liljy H, Oesterling JE: Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am 1997;24: 353-365.
26. Catalona WJ, Smith DS, Wolfert R, Wang TJ, Rittenhouse H, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214.
27. Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, Opsomer R, Wese FX: Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate 1996;(suppl)7:30.
28. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.